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Purpose: Patients with atrial ﬁbrillation are at
increased risk for stroke and thus require anticoagu-
lant prophylaxis with vitamin K antagonists. How-
ever, many such patients fail to achieve target
coagulation status. The objective of this study was
to evaluate time in the therapeutic range and its
relationship to clinical outcomes in patients with
nonvalvular atrial ﬁbrillation prescribed a vitamin K
antagonist in everyday clinical practice in 4 European
countries (France, Germany, Italy and the United
Kingdom).
Methods: Data were extracted from the European
electronic primary care database, the Longitudinal
Patient Database. Included in the analysis were 6250
adult patients for whom data on monitoring of
coagulation time and international normalized ratio
were available. The time within the therapeutic range
was estimated by using the Rosendaal method. Pa-
tients spending 470% of time within the therapeutic
range were considered to have well-controlled treat-
ment. Data on stroke and bleeding events occurring
during the study period were taken from patient
records. Stroke risk was calculated by using the
CHA2DS2-VASc score (i.e. 2 points for a history of
stroke or TIA and age 475years, and 1 point for age
between 65 and 74 years, hypertension, diabetes
mellitus, a recent cardiac failure, vascular disease
and female sex).
Findings: The proportion of patients with poorly
controlled treatment varied from 34.6% in the United
Kingdom to 55.8% in Germany. The incidence of
stroke was 0.5/100 person-years in well-controlled
patients, compared with 1.0/100 in poorly controlled1160patients. After adjustment for stroke risk factors, the
odds ratio was 1.38 (95% CI, 0.93–2.06; P ¼ 0.110).
The incidence of hemorrhage was 1.1 and 1.3 events/
100 person-years, respectively (odds ratio, 0.91 [95%
CI, 0.72–1.16]).
Implications: Many patients receiving prophylaxis
with vitamin K antagonists in everyday community
care have poorly controlled anticoagulation treatment
with vitamin K antagonists. Their international nor-
malized ratio is frequently outside the therapeutic
range, and they are thus exposed to an unnecessary
risk of stroke or bleeding complications. (Clin Ther.
2014;36:1160–1168) & 2014 The Authors. Published
by Elsevier HS Journals, Inc.
Key Words: vitamin K antagonist, warfarin, atrial
ﬁbrillation, stroke, hemorrhage, anticoagulation.INTRODUCTION
Atrial ﬁbrillation (AF) is the most frequently observed
arrhythmia in clinical practice, with an estimated
prevalence in the general population between 1%
and 2%.1–3 The prevalence increases with age, from
o0.5% between 40 and 50 years, to 5% to 15% at
480 years of age,4 with the incidence doubling for
each successive decade. In France, the number of
subjects with AF has been estimated to be between
600,000 and 1 million, with a median age at diagnosisVolume 36 Number 9
F-E. Cotte´ et al.of 75 years.5 AF affects at least 1% of the population
in Germany6 and 1.3% in Italy.7 Epidemiologic
studies in the United Kingdom have reported
prevalence rates for AF of 0.65% in subjects aged
45 to 64 years in the general population8 and 4.7% in
subjects 465 years old in primary care.9
AF is associated with high morbidity and mortal-
ity,10 in particular with an elevated risk of stroke.11,12
After controlling for age and other risk factors, the risk
for stroke is between 2 and 7 times higher than in
subjects without AF.13,14 Strokes related to AF account
for 1 in 5 strokes15 and are associated with a high
recurrence rate and worse prognosis.16 To prevent the
occurrence of stroke in patients with AF, prophylaxis
with oral anticoagulant drugs is recommended. The
American College of Chest Physicians14,17 recommends
using the CHADS2 score
18 to stratify stroke risk and
that all patients with a CHADS2 scoreZ1 receive long-
term prophylaxis with an oral anticoagulant. Guide-
lines from the European Society of Cardiology, pub-
lished in 20104 and updated in 2012,19 provide similar
advice, although they recommend the use of the
CHA2DS2-VASc as a more sensitive tool for risk
stratiﬁcation. Nevertheless, several previous studies
have shown that many patients with AF do not
receive anticoagulant prophylaxis according to
treatment guidelines and that lack of compliance with
these guidelines is associated with a higher risk of
stroke and with higher mortality.21–23
Historically, vitamin K antagonists (VKAs) have
been the mainstay of oral anticoagulant prophylaxis,
but coagulation status needs to be monitored carefully
to avoid major hemorrhagic complications, which can
be fatal.24 Coagulation status is expressed as the
international normalized ratio (INR), the target
therapeutic range being deﬁned as an INR between 2
and 3. An INR o2.0 is associated with an increased
risk of stroke, and an INR Z4 is associated with an
increased risk of major bleeding.25 The proportion of
time in the therapeutic range (TTR) thus provides a
useful measure of the level of control of cardio-
vascular risk. This parameter is a major determinant
of the efﬁcacy and safety of VKAs, with maximum
beneﬁts evident when the TTR is Z70%.26–28 Despite
the importance of maintaining an acceptable INR, it
has been estimated in randomized controlled trials that
patients spend more than one third of their time outside
the TTR.29 In a recent Italian study of 112 patients
with AF starting VKA prophylaxis at the time ofSeptember 2014hospital discharge, only 58% achieved an adequate
TTR.30 It may be expected, however, that coagulation
status in everyday practice is less well controlled than in
randomized controlled trials.31 For this reason, we
have performed a large retrospective observational
cohort (Real Evidence of AntiCoagulation Treatment
in Atrial Fibrillation) of patients with nonvalvular AF
in 4 European countries that provides an opportunity
to collect data on patients treated with VKAs. The
primary objective of the present analysis was to assess
TTR in everyday clinical practice in these patients. The
relationship between TTR and clinical outcomes was
also evaluated, but the analysis was purely exploratory.
PATIENTS AND METHODS
This was a retrospective observational cohort study of
patients with a diagnosis of nonvalvular AF conducted
in 4 European countries (France, Germany, Italy and
the United Kingdom) between May 2010 and May
2012. The study included a cross-sectional phase and
a longitudinal phase to assess the occurrence of stroke.
Data Source
Data were extracted from electronic medical re-
cords in the Longitudinal Patient Database (LPD)
managed by Cegedim Strategic Data (Boulogne Bill-
ancourt, France) and owned by Cegedim Group, a
company specialised in developing databases and
software in the ﬁeld of health. LPD is a computerized
network of general practitioners (GPs) in different
European countries who contribute extensive anony-
mous data on patient consultations and treatment to a
centralized database. The database reﬂects the regular
activity of a national sample of independent practi-
tioners, and it enables collection and longitudinal
analysis of data taken from patient records related
to prescription practices and health care consumption
in everyday clinical practice. Currently, 4500 pri-
mary care practitioners contribute to the LPD in the 4
countries of the study, providing data from routinely
collected records of 45 million patients. The LPD
database has been shown to be a reliable source of
information in numerous previous studies in several
disease areas,32–34 including AF.35,36
Study Population
All adult patients with a diagnosis of nonvalvular
AF in the LPD database who had consulted a
physician at least once during the 2-year study period1161
Clinical Therapeuticsand had been prescribed a VKA at least once were
identiﬁed. From this group, we selected those patients
for whom data on monitoring of coagulation time
were available and who had at least 2 documented
measures of INR separated byo90 days, at least once
each year since the beginning of treatment. These
patients constituted the analyzable population. For all
patients in the analyzable population, the TTR was
estimated by using the Rosendaal method.37 Patients
with a TTR 470% were considered to have well-
controlled VKA treatment.38 The analyzable
population was thus divided into 2 subgroups of
well-controlled (TTR 470%) and poorly controlled
(TTR r70%) patients.63,244 patients with atrial fibrillation
32,075 patients prescribed VKAData Collection
At the index consultation, data were extracted from
the electronic medical records on age, sex, body mass
index, date of AF diagnosis, comorbidities, history of
complications, treatments, and smoking status. Time-
dependent variables such as age were also documented
at the date of treatment initiation and treatment
discontinuation for treated patients, at the end of the
follow-up period, and at the visit before occurrence of
stroke (for patients who experienced strokes). For
patients receiving VKA medication, coagulation status
(determined by using the INR) was documented.
Stroke risk was calculated with the CHA2DS2-
VASc score.20 This is calculated by assigning 1 point
each for the presence of congestive heart failure,
hypertension, diabetes mellitus or vascular disorder,
for female sex, and for age 65 to 74 years; 2 points
were assigned each for age Z75 years and for a
history of stroke or transient ischemic attack. The
presence of comorbidities was ascertained from the
International Classiﬁcation of Diseases, 10th Revi-
sion, disease codes documented in the database.6250 patients analyzable
France
n = 1110
Germany
n = 1208
Italy
n = 1230
UK
n = 2702
Figure 1. Patient enrollment and anticoagulant
prophylaxis. VKA ¼ vitamin K anta-
gonist.Incidence of Stroke and Bleeding
Occurrence of ﬁrst stroke and bleeding was deﬁned as
the ﬁrst recording of a diagnosis of stroke in the LPD
database after the index date. The index date was deﬁned
as the date of the ﬁrst consultation during the study
period for patients with a prior diagnosis of AF and the
date of the consultation at which a diagnosis of AF was
made for newly diagnosed patients. The observation
period extended from the index date to October 31, 2012.1162Statistical Analysis
The population evaluated in this article corre-
sponded to all patients for whom data were available
for least 2 measures of INR separated by o90 days.
The analysis of the data is principally descriptive.
Data are described by using mean (SD) and median
(range) values for continuous variables and frequency
counts and percentages for categorical variables. For
selected variables, 95% CIs were calculated.
Risk of stroke and hemorrhage in patients with
suboptimal TTR was evaluated as odds ratios with
their 95% CIs. A multivariate logistic regression was
performed to adjust for potential confounding factors,
namely age, sex, CHA2DS2-Vasc score, and VKA
treatment duration. Patient follow-up data were cen-
sored after discontinuation of VKA.
Ethics
The study was performed in accordance with Good
Epidemiological Practice guidelines and relevant in-
ternational and national guidelines for pharmacoepi-
demiologic studies. Ethics board approval was not
required because the data were not nominative and
were collected retrospectively.
RESULTS
Patients
Overall, 32,075 patients prescribed a VKA were
included from the 4 participating countries (Figure 1).
Of these, sufﬁcient data on INR to determine the TTR
were available for 6250 patients (19.5%), who thus
constituted the analyzable population.Volume 36 Number 9
Table I. Demographic characteristics and stroke risk factors in patients with nonvalvular atrial fibrillation at the index consultation treated with
vitamin K antagonists (VKAs).
France
(N ¼ 16,447)
Germany
(N ¼ 13,917)
Italy
(N ¼ 22,447)
United Kingdom
(N ¼ 10,433)
Characteristic
All VKA
(n ¼ 9184)
Analyzable
(n ¼ 1110)
All VKA
(n ¼ 6386)
Analyzable
(n ¼ 1208)
All VKA
(n ¼ 8774)
Analyzable
(n ¼ 1230)
All VKA
(n ¼ 7731)
Analyzable
(n ¼ 2702)
Age, y
Mean (SD) 74.9 (10.5) 74.4 (9.6) 73.9 (9.5) 71.7 (9.5) 76.2 (9.7) 74.4 (8.4) 74.8 (10.5) 72.1 (9.7)
Median, range 77 [18–103] 76 [20–94] 75 [22–100] 73 [37–95] 78 [21–112] 75 [23–111] 76 [18–102] 73 [29–98]
o75 y 3766 (41.0%) 480 (43.2%) 3059 (47.9%) 681 (56.4%) 3160 (36.0%) 571 (46.4%) 3305 (42.7%) 1520 (56.3%)
Z75 y 5418 (59.0%) 630 (56.8%) 3327 (52.1%) 527 (43.6%) 5614 (64.0%) 659 (53.6%) 4426 (57.3%) 1182 (43.7%)
Sex
Male 5714 (62.2%) 636 (57.3%) 3460 (54.2%) 622 (51.5%) 4456 (50.8%) 580 (47.2%) 4434 (57.4%) 1527 (56.5%)
Female 3470 (37.8%) 474 (42.7%) 2926 (45.8%) 586 (48.5%) 4318 (49.2%) 650 (52.8%) 3297 (42.6%) 1175 (43.5%)
Medical sroke risk factors
Diabetes 2090 (22.8%) 280 (25.2%) 2724 (42.7%) 467 (38.7%) 2263 (25.8%) 359 (29.2%) 1154 (14.9%) 410 (15.2%)
Arterial hypertension 6502 (70.8%) 808 (72.8%) 5316 (83.2%) 1008 (83.4%) 6395 (72.9%) 935 (76.0%) 2255 (29.2%) 796 (29.5%)
Coronary heart disease 1437 (15.6%) 201 (18.1%) 2834 (44.4%) 493 (40.8%) 1955 (22.3%) 290 (23.6%) 1696 (21.9%) 545 (20.2%)
Heart failure 1454 (15.8%) 1262 (20.2%) 1966 (30.8%) 340 (28.1%) 1730 (19.7%) 262 (21.3%) 1339 (17.3%) 438 (16.2%)
Vascular disease 1178 (12.8%) 806 (12.9%) 1239 (19.4%) 236 (19.5%) 947 (10.8%) 153 (12.4%) 724 (9.4%) 246 (9.1%)
History of stroke or TIA 1042 (11.3%) 998 (16.0%) 998 (15.6%) 200 (16.6%) 1118 (12.7%) 181 (14.7%) 1245 (16.1%) 463 (17.1%)
CHA2DS2-VASc score
*
Mean (SD 2.7 (1.6) 3.3 (1.6) 3.1 (1.8) 3.0 (1.8) 3.0 (1.7) 3.5 (1.6) 2.3 (1.5) 2.5 (1.5)
Median [range] 3 [0–9] 3 [0–8] 3 [0–9] 3 [0–9] 3 [0–9] 3 [0–9] 2 [0–9] 2 [0–8]
Z1 8323 (90.6%) 1065 (95.9%) 5994 (93.9%) 1118 (92.5%) 8246 (94.0%) 1087 (88.4%) 6702 (86.7%) 2449 (90.6%)
Z2 6912 (75.3%) 950 (85.6%) 5090 (79.7%) 953 (78.9%) 7057 (80.4%) 143 (11.6%) 5154 (66.7%) 1970 (72.9%)
TIA ¼ transient ischemic attack.
CHA2DS2-VASc score : 2 points for a history of stroke or TIA and age >75years, and 1 point for age between 65 and 74 years, hypertension, diabetes mellitus,
a recent cardiac failure, vascular disease and female sex.
*At the time of diagnosis of atrial ﬁbrillation or the time that treatment was initiated, whichever came later. F-E
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Clinical TherapeuticsDemographic data for all patients receiving VKAs,
as well as for the 6250 patients in the analyzable
population, are provided in Table I, together with
information on the CHA2DS2-VASc stroke risk
scores. The median CHA2DS2-VASc score was 3 in
all countries except the United Kingdom (median, 2).
Some differences were observed between the analyz-
able population and all the study patients prescribed a
VKA. In all countries, the analyzable population tended
to be younger, with a higher proportion of women.VKA Treatment and Monitoring
The most widely prescribed VKAs were warfarin in
Italy and the United Kingdom, ﬂuindione in France, and
phenprocoumon in Germany (Table II). The median
duration of treatment was 4 years in all countries except
the United Kingdom (5 years). On average, the INR was
determined at least 9 times per year in all countries. The
mean TTR ranged from 66.0% in Italy to 72.6% in the
United Kingdom. In France, Germany, and Italy,
o50% of the patients were considered to have well-
controlled VKA treatment (TTR 470%) and up to
20% spent o50% of their time outside the therapeutic
range. The proportion of patients spending more TTR
was higher in the United Kingdom.Table II. Prescription of vitamin K antagonists (VKAs).
Variable
France
(n ¼ 1110)
Individual VKA*
Warfarin 97 (8.7%)
Acenocoumarol 68 (6.1%)
Fluindione 945 (85.1%)
Phenprocoumon —
Phenindione —
Duration of VKA treatment, y
Median [range] 4 [1–13]
Determination of INR
Mean no. of measures/patient 37.5 (32.4)
Mean no. of measures/patient/year 9.61 (5.86)
Median no. of measures/patient/year 9.14 [1.0–39.0]
Time spent in therapeutic range, % Mean (SD) 66.2 (21.1)
INR in therapeutic range
o50% of the time 209 (18.8%)
50%–70% of the time 370 (33.3%)
470% of the time 531 (47.8%)
INR ¼ international normalized ratio.
*Because certain patients were prescribed 41 VKA, these treatm
1164TTR and Stroke and Bleeding Risk
The association between the time spent in the
therapeutic range and the incidence of stroke and
hemorrhage was investigated (Figure 2). To optimize
the power of the analysis, data were pooled across the
4 participating countries. Overall, 105 ischemic
strokes were documented for 14,836 patient-years of
VKA prescription. These strokes were more frequent
in patients who had a TTR r70% (1.0 stroke/100
person-years) than in patients whose coagulation
status was well controlled (0.5 stroke/100 person-
years). The unadjusted odds ratio for stroke was 1.60
(95% CI, 1.08–2.36; P ¼ 0.019). After adjustment for
age, sex, treatment duration, and CHA2DS2-Vasc
score, the adjusted odds ratio was 1.38 (95% CI,
0.93 – 2.06), which was no longer signiﬁcant (P ¼
0.110). In terms of hemorrhage, 291 bleeding events
were documented, including 55 gastrointestinal hem-
orrhages and 24 hemorrhagic strokes. The frequency
of events was somewhat lower in patients who had
well-controlled VKA treatment (1.1 vs 1.3 events/100
person-years). No signiﬁcant association was observed
between hemorrhage rate and TTR, either in the
unadjusted analysis (odds ratio, 1.00 [95% CI,
0.79–1.27]; Po 0.098) or the adjusted analysis (odds
ratio, 0.91 [95% CI, 0.72–1.16]; P ¼ 0.45).Germany
(n ¼ 1208)
Italy
(n ¼ 1230)
United Kingdom
(n ¼ 2702)
7 (0.6%) 1091 (88.7%) 2697 (99.8%)
— 139 (11.3%) 2 (0.1%)
— — —
1201 (99.4%) — —
— — 3 (0.1%)
4 [1–10] 4 [1–14] 5 [1–13]
38.4 (30.0) 49.0 (40.7) 74.7 (48.8)
9.48 (4.49) 9.78 (5.40) 13.07 (5.46)
9.25 [1.5–23.0] 10.0 [1.0–42.7] 12.36 [1.5–51.5]
65.3 (19.6) 66.0 (18.4) 72.6 (13.7)
232 (19.2%) 192 (15.6%) 156 (5.8%)
441 (36.5%) 471 (38.3%) 779 (28.8%)
535 (44.2%) 567 (46.1%) 1767 (65.4%)
ents are not mutually exclusive.
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Figure 2. Rate of occurrence of stroke or bleed-
ing as a function of time spent in
therapeutic range. Data are presented
as mean values with their 95% CIs.
F-E. Cotte´ et al.DISCUSSION
This study evaluated patients with nonvalvular AF
treated with VKA in everyday care in 4 European
countries. We observed that a majority of the patients
in France (52%), Germany (56%), and Italy (54%) had a
TTR r70%. The situation in the United Kingdom was
somewhat better, with approximately one third of
patients presenting with a TTR o70% (35%). Com-
pared with the other countries, patients with AF in the
United Kingdom differed in having a lower stroke risk,
more frequently evaluated INR, and a higher TTR. These
differences may be explained by the care paradigm in the
United Kingdom: such patients are managed by physi-
cians in specialized “warfarin clinics,” where INR is
frequently controlled and the dose of VKA is adapted. It
is also noteworthy that different VKAs were used in
different countries: warfarin accounted for the large
majority of VKA use in Italy and the United Kingdom,
phenprocoumon in Germany, and ﬂuindione in France.
Comparative data on the effectiveness of these VKAs in
everyday practice are extremely limited, and it is possible
that differences in the VKAs prescribed may contribute to
some of the between-country variation in TTR observed.
The relation between TTR and clinical outcome was
also evaluated, although it should be noted that this
analysis was purely exploratory, and the study was
neither designed nor powered to address this factor.September 2014When the data were pooled across countries, we
observed a higher frequency of stroke in these poorly
controlled patients (1.0 stroke/100 person-years) com-
pared with those with a TTR 470% (0.5 stroke/100
person-years). However, when adjusted on stroke risk
factors, the odds ratio did not reach statistical signiﬁ-
cance. Sample attrition may have provided less power to
our analysis, and the observed trend should be evaluated
in a larger population. The absence of a similar trend for
hemorrhage is surprising but could be explained by the
fact that patients with uncontrolled VKA treatment may
be more often below the intended INR therapeutic range
than above. This phenomenon has been observed
previously39 and may reﬂect a tendency of GPs to
underdose VKAs because of possible adverse effects
related to concerns about VKA-associated hemorrhage.
This study has several limitations, principally linked to
the use of electronic general practice databases. These
databases provide information on a large number of
patients gathered in real-life conditions by a representa-
tive national sample of GPs. However, because the data
are collected in everyday clinical practice, their availabil-
ity depends on the assiduity of the GP in using the
medical software. Whereas basic data on patient charac-
teristics, diseases, and drug prescriptions are generally
collected comprehensively by all GPs, information on
paraclinical tests such as INR assays may only be
documented in the electronic database by some GPs
some of the time. Calculation of the TTR requires regular
assay and documentation of the INR, which could
explain why only 20% of the patients in our survey
were considered analyzable in the 4 countries considered.
The low proportion of analyzable patients may have
introduced some inclusion bias with respect to all patients
with AF who consult their GP. Indeed, in all 4 countries,
the analyzable populations tended to be younger and
more frequently women, although their stroke risks were
similar to those of the entire study sample. Generally
speaking, the characteristics of the AF patients evaluated
were consistent with previous ﬁndings from real-life
cohorts in France,40 Germany,41 and Italy.42
With such databases, it is impossible to ensure that
all medical events are exhaustively documented, partic-
ularly if they are not the speciﬁc objective of the GP
consultation. Thus, it is useful to compare the event
rates documented in our study with those reported in
dedicated patient cohorts in real-life conditions of care.
For example, in a cohort of 3302 patients with AF in
Italy,39 the rates of stroke (0.76 event/100 patient-years)1165
Clinical Therapeuticsand bleeding events (1.24 events/100 patient-years)
were similar to those reported in the present study.
Conversely, in the United Kingdom and France,
although the incidence of stroke is consistent with
what has been observed previously in real-life studies
(0.9 and 1.2 events/100 patient-years, respectively), the
incidence of hemorrhage in the present study appeared
to be lower than expected from these earlier studies (3.8
and 3.2 events/100 patient-years, respectively).43,44 This
discrepancy could be attributable, at least in part, to the
fact that bleeding events may be managed elsewhere
than in primary care, and events that are not serious or
without consequences may go undocumented.
CONCLUSIONS
This study of the management of AF in primary care
in 4 European countries indicates that many patients
receiving VKA prophylaxis did not achieve their target
coagulation status, with their INR frequently outside
the therapeutic range, and are thus exposed to an
unnecessary risk of stroke or bleeding complications.
A trend toward a higher incidence of stroke in patients
who fail to achieve target levels was observed.
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